Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: Susceptibility and clinical outcome

References

• Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254–63.
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775–80.
   PubMed Web of Science ®Google Scholar
• Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, . Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J Infection 2009;58:273–84.
   PubMed Web of Science ®Google Scholar
• Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, . A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62(Suppl 1):i29–40.
   PubMedGoogle Scholar
• Vila J, Pachon J. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008;9: 587–99.
   PubMed Web of Science ®Google Scholar
• Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46: 567–70.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010;10:287.
   PubMed Web of Science ®Google Scholar
• Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, . Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008;61: 729–33.
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980–7.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008;62:45–55.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, . Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128–31.
   PubMed Web of Science ®Google Scholar
• Kuo SC, Wang FD, Fung CP, Chen LY, Chen SJ, Chiang MC, . Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 2011;44:45–51.
   PubMedGoogle Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–29.
   PubMed Web of Science ®Google Scholar
• Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, . Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009;31:146–50.
   PubMed Web of Science ®Google Scholar
• Wyeth. TYGACIL^®(tigecycline) FOR INJECTION for intravenous use. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2011.
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, eighth edition. M07-A8. Wayne, PA: CLSI; 2009.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100‐S20. Wayne, PA: CLSI; 2010.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website (EUCAST version 5.13). EUCAST; 2012.
   Google Scholar
• Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;59:772–4.
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41(Suppl 5):S333–40.
   Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220–9.
   PubMed Web of Science ®Google Scholar
• Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002;8:687–93.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, . Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–96.
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, . Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, . Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140–51.
   PubMed Web of Science ®Google Scholar
• Jean SS, Hsueh PR. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 2011;12:2145–8.
   PubMed Web of Science ®Google Scholar